UBS AM’s Lifecore Biomedical LFCR Stock Holding History

UBS AM’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-18,399	Closed	-$224K	–	2549
2013 Q3	$224K	Hold	18,399	–	–	﹤0.01%	2273
2013 Q2	$243K	Buy	+18,399	New	+$254K	﹤0.01%	2149

Other funds holding LFCR

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS AM's LFCR Position: Q4 2013 in Review

UBS AM sold out of Lifecore Biomedical (LFCR) in Q4 2013, closing a stake of 18,399 shares — an estimated $224K sold.

UBS AM first reported a position in LFCR in Q2 2013 and held it in 2 quarters. The position peaked at $243K in Q2 2013. 111 funds tracked by Wall St. Rank hold LFCR as of Q4 2013.

UBS AM reported no remaining Lifecore Biomedical position as of Q4 2013 after selling out during the quarter.
UBS AM sold 18,399 Lifecore Biomedical shares in Q4 2013, an estimated $224K.
UBS AM first reported a position in Lifecore Biomedical in Q2 2013 and held it in 2 quarters.
UBS AM's Lifecore Biomedical position peaked at $243K in Q2 2013.
111 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2013.

Based on UBS AM's 13F filing for Q4 2013, filed 31 Jan 2014.